Efficacy and safety of capmatinib: the latest authoritative evaluation!

Capmatinib (Capmatinib) is an inhibitor of MET protein kinase, which has been widely studied and used in NSCLC skipping mutants of METexon 14. The efficacy and safety of capmatinib are discussed in detail below, based on past clinical trial data.

Effectiveness:

1.Objective response rate (ORR): Capmatinib has shown a high objective response rate in patients with METexon14skipping mutantNSCLC in multiple clinical trials. This means that after treatment, the patient experienced a significant slowdown in the size, number, or spread of tumors.

2.Prolonged survival: Some studies have shown that capmatinib can significantly extend the overall survival of patients. This is an important indicator of treatment effectiveness and shows the drug's potential to improve a patient's overall survival.

3.Progression survival (PFS): Capmatinib also showed good results in improving the progression survival of patients. PFS refers to the time that a patient’s disease no longer progresses during treatment. Longer PFS is usually associated with better treatment effects.

4.Efficacy in specific subgroups: Some studies have found that capmatinib is particularly effective in patients with METExon14skipping mutationNSCLC, providing a promising treatment option for this specific subgroup of patients.

Overall, capmatinib showed encouraging efficacy in METExon14skipping mutantNSCLC patients, providing an effective treatment option for patients.

Security:

1.Common adverse reactions: In clinical trials, common adverse reactions of capmatinib include but are not limited to nausea, fatigue, diarrhea, abnormal liver function, etc. These reactions are usually mild to moderate and can be relieved with appropriate management.

2.Serious adverse events: Although capmatinib is generally considered a relatively safe drug, in some cases, serious adverse events, such as hypertension, pneumonia, etc., may occur. Therefore, the patient's condition and physiological parameters require close monitoring while using capmatinib.

3.Treatment-related toxicities: Like many targeted therapies, capmatinib may cause some treatment-related toxicities. This may include skin reactions, digestive tract problems, etc., which require timely detection and effective intervention.

4.Safety assessment: In clinical practice, researchers and doctors usually conduct regular safety assessments on patients to ensure that the use of drugs is safe and will not cause adverse effects on the patient's overall health.

When efficacy and safety data are considered together, capmatinib is considered an effective and relatively safe treatment option in patients with METExon14skipping mutantNSCLC. However, treatment decisions should be based on a joint discussion between physician and patient and take into account the individual patient's condition and needs. Additionally, over time, new studies and data may further refine the understanding of capmatinib.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.